Biography

Dr Ru-Dee Ting qualified as a cardiologist in 2009, completing his advanced training at the Royal Prince Alfred Hospital. Subsequently, he undertook a PhD and a Masters of Clinical Trials with the University of Sydney at the NHMRC Clinical Trials Centre and the Heart Research Institute. His research examined the impact of renal disease on cardiovascular risk and the effect of fenofibrate on the microvascular complications of diabetes. He is currently a clinical lecturer with the University of Sydney clinical school and a senior clinical lecturer at the Macquarie University clinical school.

Dr Ting sub-specialises in interventional cardiology. He completed his fellowship at St Michael’s Hospital, University of Toronto, training in coronary angiography, right heart studies, intracoronary imaging and coronary angioplasty. In addition, he trained in structural intervention including atrial septal defect and patent foremen ovale closure, MitraClip and transcutaneous aortic valve implantation. He practices at the Sydney Adventist Hospital, Macquarie University Private Hospital and Norwest Private Hospital.

Dr Ting speaks English and Mandarin.

Procedures & Conditions

Procedures Performed
  • Transcatheter Aortic Valve Implantation (TAVI)
  • MitraClip Transcatheter Mitral Valve Repair Device
  • Atrial Septal Defect (ASD) Closures
  • Patent Foramen Ovale (PFO) Closures
  • Percutaneous Coronary Intervention (PCI)
Conditions Treated
  • Aortic Stenosis
  • Structural Heart Disease

Experience

  • Clinical Senior Lecturer
    Macquarie University 2016-Present
  • Clinical Lecturer
    University of Sydney 2016-Present
  • Inventional Cardiologist
    Sydney Cardiology Group 2015-Present
  • Structural Heart Disease Fellow
    St Michael's Hospital, Toronto 2013-2014
  • Fellowship in Cardiology
    Royal Australasian College of Physicians 2010
  • Cardiology Advanced Training
    Royal Prince Alfred Hospital 2008-2009
  • Honorary Associate - Clinical Research & Epidemiology at the NHMRC Clinical Trials Centre
    The University of Sydney 2007-2009
  • Advanced Trainee General Medicine
    Royal Prince Alfred Hospital 2007
  • FRACP BPT3
    Royal Prince Alfred Hospital 2006
  • FRACP BPT2
    Royal Melbourne Hospital 2005
  • Medical Resident
    St Vincent's Hospital (Melbourne) 2003-2004

Research & Publications

Publications

1. R. Ting and P.L Drury et al. “Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study”, Diabetologia 2011; 54(1): 32-43

2. R. Ting and T.M.E Davis et al. “Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study”, Diabetologia 2011;  54(2): 28090

3. R. Ting and A.C. Keech et al. “Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD study”, Diabetes Care 2012; 35:218-25

4. G.J. Hankey et al. “Rates and predictors of risk of stroke and its subtypes in diabetes: a prospective observational study”, Journal of Neurology, Neurosurgery and Psychiatry 2013; 84(3):281-7

5. R. Ting, A.C. Keech. “Fenofibrate and renal disease: clinical effects in diabetes”, Clinical Lipidology 2013; 8 (6): 669–80

6. R. Ting et al. “Repatriation to Referral Hospital After Reperfusion of STEMI Patients Transferred for Primary Percutaneous Coronary Intervention: Insights of a Canadian Regional STEMI Care System”, American Heart Journal, in-press.

7. “A Systemic Review and Meta-Analysis of Two-Stent Techniques for the Treatment of Coronary Bifurcation Lesions”. Society for Cardiovascular Angiography and Interventions 2014 Scientific Sessions (May), Las Vegas, USA. Catheterization and Cardiovascular Interventions 2014; 83 (S1): S59.

8. Challenging Case: “A Case of Extra Backup Being Insufficient”. Transcatheter Cardiovascular Therapeutics Conference (September), Washington, DC, USA

9. “A Systemic Review and Meta-Analysis of Two-Stent Techniques for the Treatment of Coronary Bifurcation Lesions”. Canadian Cardiovascular Congress, Vancouver, Canada (October)

10. “Risk Predictors of Lower-limb Amputation in Patients with Type 2 Diabetes Mellitus in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study”. Cardiac Society of Australia and New Zealand Annual Scientific Meeting (Aug), Perth Australia

11. “Cardiovascular and Renal Safety of Fenofibrate in the FIELD Study”. European Atherosclerotic Society Congress (June), Hamburg Germany. Atherosclerosis supplements 2010; 11(2): 219

12. “Fenofibrate Reduces Peripheral Neuropathy in Type 2 Diabetes: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study”. European Atherosclerotic Society Congress (June), Hamburg Germany. Atherosclerosis supplements 2010; 11(2): 219-20

13. “Clinical and Biochemical Indicators and Predictors of microvascular complications of type 2 diabetes mellitus: the FIELD study”. American Heart Association Annual Scientific Meeting (Nov), Orlando USA

14. “Clinical and Biochemical Indicators of microvascular complications of type 2 diabetes mellitus: the FIELD study”. Australian Diabetes Society Annual Scientific Meeting (Aug), Adelaide Australia

View More

Presentations

  • “Renal disease: Bedside to Bench”, Vascular Risk Masterclass (Nov 2011), Melbourne Australia.
  • “Effect of Fenofibrate on Cardiovascular Events According to Changes in Plasma Creatinine Levels during the Pre-Randomization Period: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study”, American Society of Nephrology Kidney Week (Nov 2011), Philadelphia, USA
  • “Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes mellitus and renal impairment – the FIELD study”, European Society of Cardiology Annual Scientific Congress (Aug 2011)
  • “Rates and risk predictors of stroke and its subtypes among people with diabetes mellitus”, European Society of Cardiology Annual Scientific Congress (Aug 2011)
  • “Cardiovascular Risk, Renal Status and Fenofibrate Safety in the FIELD Study”, Cardiac Society of Australia and New Zealand Annual Scientific Meeting (Aug 2011), Perth Australia
  • “Effects of Fenofibrate on renal endpoints and safety issues”, NHMRC CTC visiting scientist seminar (Apr 2011), Sydney
  • “Effects of fenofibrate on measures of renal function in type 2 diabetes mellitus: the FIELD study” Vascular Risk Masterclass (Nov 2010), Melbourne Australia.
  • “Renal and Cardiovascular Safety of Fenofibrate in the FIELD Study”. Australian Diabetes Society Annual Scientific Meeting (Sept 2010), Sydney Australia.
  • “Effects of fenofibrate on measures of renal function in type 2 diabetes mellitus: the FIELD study” Vascular Risk Masterclass (Nov 2009), Melbourne Australia.
View More